3BLICK SK, SCOTT LJ. Cetuximab: a review of its use insquamous cell carcinoma of the head and neck and metastaticcolorectal cancer[J]. Drugs, 2007, 67(17) : 2585-2607.
4MENDELSOHN J, BASELGA J. Status of epidermal growthfactor receptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol, 2003, 21(14): 2787-2799.
6FAKIH M,VINCENT M. Adverse events associated with anti -EGFR therapies for the treatment of metastatic colorectal cancer[J]. Curr Oncol, 2010,17 Suppl 1 : S18-S30.
7MITCHELL EP,PEREZ-SOLER R, VAN CE, et al. Clinicalpresentation and pathophysiology of EGFRI dermatologictoxicities [J]. Oncology (Williston Park),2007, 21 (11 Suppl5): 4-9.
8MAKOTO K, MADOKA S, MEGUMU M,et al. Cetuximab -induced skin reactions are suppressed by cigarette smoking inpatients with advanced colorectal cancer [J]. Int J Clin Oncol,2012[Epub ahead of print].
9OUWERKERK J, BDERS - DOETS C. Best practices in themanagement of toxicities related to anti - EGFK agents formetastatic colorectal cancer[J]. Eur J Oncol Nurs, 2010, 14(4):337-349.
10GARRETT CR, ENG C. Cetuximab in the treatment of patientswith colorectal cancer[J]. Expert Opin Biol Ther, 2011,11(7):937-949.
